Early Imaging Detection of CV Injury after Cancer

癌症后心血管损伤的早期影像检测

• 批准号: 8478069
• 负责人: William Gregory Hundley
• 金额: $ 47.89万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-06-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8478069
• 关键词: 10 year old; Accounting; Adjuvant; Adult; Age; Anthracyclines; Aorta; Asians; Atherosclerosis; Breast Cancer Treatment; Cancer Survivor; Cardiac; Cardiac Death; Cardiovascular Diseases; Cardiovascular system; Case Study; Caucasians; Caucasoid Race; Chemotherapy-Oncologic Procedure; Child; Clinical; Clinical Research; Collaborations; Comorbidity; Computer software; Congenital Heart Defects; Congestive Heart Failure; Coronary Arteriosclerosis; Data; Data Element; Data Quality; Detection; Development; Diabetes Mellitus; Disease; EFRAC; Early Diagnosis; Etiology; Event; Exposure to; Fibrosis; Funding; Future; Gender; Guidelines; Health Sciences; Heart; Hispanics; Hypertension; Image; Individual; Injury; Institution; Investigation; Left; Left Ventricular Function; Lymphoma; Magnetic Resonance Imaging; Malignant Neoplasms; Matched Group; Measures; Medical center; Methodology; Metric; Monitor; Morbidity - disease rate; Myocardial; Myocardial Infarction; NIH Program Announcements; Participant; Patients; Persons; Physiologic pulse; Population; Population Projection; Procedures; Race; Relative (related person); Reporting; Research; Research Personnel; Risk; Risk Factors; Scientist; Secondary to; Series; Signal Transduction; Smoking; Solutions; Specific qualifier value; Standardization; Stroke; Survivors; Technology; Testing; Therapeutic Intervention; Time; Translating; Translations; Treatment Protocols; Universities; Validation; Ventricular; aged; base; cardiovascular imaging; cardiovascular injury; cardiovascular risk factor; case control; chemotherapy; cohort; cost; cost effective; design; forest; imaging modality; improved; in vivo; innovation; leukemia/lymphoma; malignant breast neoplasm; mortality; neglect; new technology; outcome forecast; population based; pre-clinical; pre-clinical therapy; prevent; prototype; systems research

DESCRIPTION (provided by applicant): Cardiovascular (CV) injury leading to myocardial infarction (MI), cardiac death, stroke, and congestive heart failure (CHF) is a major impediment to the curative use of anthracycline-based chemotherapy for the treatment of adjuvant breast cancer, leukemia, and lymphoma. No clinically acceptable alternatives exist for children or adults that require this therapy. The assembled academic-industrial team will develop and optimize a cost-effective, automated, reproducible hardware/software platform that acquires, analyzes, and reports subclinical and clinical CV injury, identifies the mechanisms of this injury and forecasts CV event risks. This important information can be utilized for preclinical treatment protocols that, when administered to other high CV risk populations, reduce the rates of adverse CV events. This well-designed and powered pivotal clinical study to validate these technologies will: " Collect within person longitudinal results before anthracycline exposure and at 3 and 24 months after exposure to determine if short-term results predict long-term subclinical disease that portends an adverse prognosis~ " Determine the efficacy of this new platform in children and adults aged 10 to 80 years~ " Derive population (age, gender, race, and cardiac risk factor-matched) predictive metrics for the platform compared against 6,000 individuals without known coronary artery disease from the existing Multi-Ethnic Study of Atherosclerosis (MESA)~ " Standardize the automated platform to enable medical centers throughout the world with little MRI expertise to reliably and reproducibly perform the studies. This platform innovation is based on strong NCI funded preliminary data and provides a highly significant cost effective solution for a previously unsolved clinical problem that noninvasively defines early CV risk and enables targeted therapeutic interventions to dramatically reduce these risks. Reducing CV events in cancer survivors will reduce overall morbidity in patients with cancer and improve cancer-related survival.

描述（由申请人提供）：导致心肌梗塞（MI）、心源性死亡、中风和充血性心力衰竭（CHF）的心血管（CV）损伤是基于蒽环类药物的化疗用于辅助治疗的主要障碍乳腺癌、白血病和淋巴瘤。对于需要这种治疗的儿童或成人来说，不存在临床上可接受的替代方案。聚集的学术工业团队将开发和优化一个经济高效、自动化、可重复的硬件/软件平台，该平台获取、分析和报告亚临床和临床心血管损伤，识别这种损伤的机制并预测心血管事件风险。这一重要信息可用于临床前治疗 当对其他高心血管风险人群进行治疗时，可以降低不良心血管事件的发生率。这项精心设计、有力的关键临床研究旨在验证这些技术，将：“收集蒽环类药物暴露前以及暴露后 3 个月和 24 个月的人体纵向结果，以确定短期结果是否预示着预示不良预后的长期亚临床疾病~“确定这个新平台对 10 至 80 岁儿童和成人的功效~”导出该平台的人群（年龄、性别、种族和心脏危险因素匹配）预测指标来自现有多种族动脉粥样硬化研究 (MESA) 的 6,000 名没有已知冠状动脉疾病的个体〜“标准化自动化平台，使世界各地缺乏 MRI 专业知识的医疗中心能够可靠且可重复地进行研究。 该平台创新基于 NCI 资助的强大初步数据，为之前未解决的临床问题提供了极具成本效益的解决方案，以无创方式定义早期 CV 风险，并实现有针对性的治疗干预，以显着降低这些风险。减少癌症幸存者的心血管事件将降低癌症患者的总体发病率 癌症并提高癌症相关的生存率。